By Dean Seal
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
The biotechnology company said Monday that DNL343 didn't meet the primary endpoint of slowing disease progression as compared with a placebo. Secondary endpoints measuring muscle strength and respiratory function weren't statistically different between active and placebo groups.
The treatment was found to be safe and well tolerated, and further analyses are anticipated later this year.
"Though the initial top-line clinical results of this trial were not what we hoped, the data collected is valuable in helping to understand the next stage of ALS research," said Merit Cudkowicz, the principal investigator of the trial.
Shares fell 7.7% to $18.30 in after-market trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 06, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。